Alps Advisors Inc Bluebird Bio, Inc. Transaction History

Alps Advisors Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 09, 2022	SELL	$8.96 - $16.31 $742,165 - $1.35 Million	-82,831 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$11.24 - $21.0 $61,898 - $115,647	-5,507 Reduced 6.23%	82,831 $1.58 Million
Q2 2021 Aug 11, 2021	SELL	$18.04 - $22.09 $572,697 - $701,269	-31,746 Reduced 26.44%	88,338 $2.83 Million
Q1 2021 May 07, 2021	BUY	$16.59 - $33.89 $6,420 - $13,115	387 Added 0.32%	120,084 $3.62 Million
Q4 2020 Feb 03, 2021	BUY	$27.5 - $37.92 $3.29 Million - $4.54 Million	119,697 New	119,697 $5.18 Million
Q2 2020 Aug 05, 2020	SELL	$27.12 - $45.97 $2.72 Million - $4.61 Million	-100,343 Closed	0 $0
Q1 2020 May 06, 2020	SELL	$26.16 - $63.5 $292,468 - $709,930	-11,180 Reduced 10.02%	100,343 $4.61 Million
Q4 2019 Feb 07, 2020	BUY	$46.96 - $61.67 $5.24 Million - $6.88 Million	111,523 New	111,523 $9.79 Million
Q2 2018 Jul 25, 2018	SELL	$99.64 - $127.59 $157,530 - $201,719	-1,581 Closed	0 $0
Q1 2018 May 01, 2018	BUY	$105.8 - $150.94 $167,269 - $238,636	1,581 New	1,581 $270,000
Q4 2017 Feb 05, 2018	SELL	$81.25 - $130.7 $3.65 Million - $5.87 Million	-44,898 Closed	0 $0
Q3 2017 Nov 03, 2017	BUY	$57.74 - $91.42 $2.59 Million - $4.1 Million	44,898	44,898 $6.17 Million

151

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $28.5M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Alps Advisors Inc, based on Form 13F filings with the SEC.

Stay updated on Alps Advisors Inc with notifications on news.